ArticleAntibiotics (Basel, Switzerland)2021
An Antibacterial Peptide with High Resistance to Trypsin Obtained by Substituting d-Amino Acids for Trypsin Cleavage Sites.
Article in Antibiotics (Basel, Switzerland), 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed.
- In Vitro Screening of Short Synthetic Antimicrobial Peptides Toward Food-Relevant Microorganisms: Antifungal Activity and Molecular Docking Analysis.Microorganisms · 2026Article
- Targeting Bacterial Infections in Periodontal Disease: From Conventional Antibiotics to Next-Generation Therapeutics.Antibiotics (Basel, Switzerland) · 2026Review
- Antibacterial Activity of the Pyrazolone Copper Complex P-FAH-Cu-phen AgainstMicroorganisms · 2026Article
- Peptide-based ligand antagonists block a Vibrio cholerae adhesin.FEBS letters · 2026Article
- A Novel Type I Crustin Isoform from Scylla olivacea and its Antibacterial Potential: Membrane Depolarization, Disruption, and Induction of Reactive Oxygen Species as Modes of Action.Probiotics and antimicrobial proteins · 2025Article
- Utilizing Proteolytic-Resistant Nano-Short Peptide Based on Naphthyl Tail-Anchored to Combat Bacterial Infections.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2025Article
- Screening and Validation of Functional Residues of the Antimicrobial PeptideBiomolecules · 2025Article
- Targeted Modification of the Antimicrobial Peptide DGL13K Reveals a Naturally Optimized Sequence for Topical Applications.Microorganisms · 2025Article
- Development of Broad-Spectrum Antimicrobial Peptides through the Conjugation of FtsZ-Binding and Cell-Penetrating Peptides.ACS infectious diseases · 2025Article
- Forging a New Frontier: Antimicrobial Peptides and Nanotechnology Converging to Conquer Gastrointestinal Pathogens.Small (Weinheim an der Bergstrasse, Germany) · 2025Review
- Unlocking the power of antimicrobial peptides: advances in production, optimization, and therapeutics.Frontiers in cellular and infection microbiology · 2025Review
- Development of lysine-branched dendrimeric antimicrobial peptides targeting ESKAPE pathogens: broad-spectrum activity, biofilm eradication, and endotoxin neutralization.Frontiers in microbiology · 2025Article
- Modification approaches of walnut proteins to improve their structural and functional properties: A review.Food chemistry: X · 2024Article
- Guanethidine Enhances the Antibacterial Activity of Rifampicin Against Multidrug-Resistant Bacteria.Microorganisms · 2024Article
- Guanethidine Restores Tetracycline Sensitivity in Multidrug-ResistantAntibiotics (Basel, Switzerland) · 2024Article
- Novel multidomain peptide self-assembly biomaterials based on bola structure and terminal anchoring: Nanotechnology meets antimicrobial therapy.Materials today. Bio · 2024Article
- Recent Advances in Amphipathic Peptidomimetics as Antimicrobial Agents to Combat Drug Resistance.Molecules (Basel, Switzerland) · 2024Review
- Antimicrobial resistance expansion in pathogens: a review of current mitigation strategies and advances towards innovative therapy.JAC-antimicrobial resistance · 2023Review
- Famotidine Enhances Rifampicin Activity against Acinetobacter baumannii by Affecting OmpA.Journal of bacteriology · 2023Article
- Advances of Antimicrobial Peptide-Based Biomaterials for the Treatment of Bacterial Infections.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2023Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
The poor stability of antibacterial peptide to protease limits its clinical application. Among these limitations, trypsin mainly exists in digestive tract, which is an insurmountable obstacle to orally delivered peptides. OM19R is a random curly polyproline cationic antimicrobial peptide, which has high antibacterial activity against some gram-negative bacteria, but its stability against pancreatin is poor. According to the structure-activity relationship of OM19R, all cationic amino acid residues (l-arginine and l-lysine) at the trypsin cleavage sites were replaced with corresponding d-amino acid residues to obtain the designed peptide OM19D, which not only maintained its antibacterial activity but also enhanced the stability of trypsin. Proceeding high concentrations of trypsin and long-time (such as 10 mg/mL, 8 h) treatment, it still had high antibacterial activity (MIC = 16-32 µg/mL). In addition, OM19D also showed high stability to serum, plasma and other environmental factors. It is similar to its parent peptide in secondary structure and mechanism of action. Therefore, this strategy is beneficial to improve the protease stability of antibacterial peptides.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.